A 72-year-old man with a history of hypertension and diabetes mellitus presents with bone pain in the lumbar spine and pelvis for 3 weeks. PSA is markedly elevated at 145 ng/mL. Serum alkaline phosphatase is 89 U/L (normal 30–120). Bone scan shows multiple hot spots in the lumbar vertebrae, pelvis, and femur. Biopsy of a pelvic lesion confirms adenocarcinoma of the prostate. Serum testosterone is 450 ng/dL (normal 300–1000). What is the most appropriate first-line hormonal agent for this patient?

Explanation

## Clinical Scenario This patient has **metastatic castration-sensitive prostate cancer (mCSPC)** with: - Markedly elevated PSA (145 ng/mL) - Symptomatic bone metastases (pain, hot spots on bone scan) - Testosterone in the normal range (450 ng/dL) — **not yet castrated** ### First-Line Hormonal Therapy for mCSPC **Key Point:** The gold standard for newly diagnosed mCSPC is **complete androgen blockade (CAB)** with a GnRH agonist/antagonist PLUS an androgen receptor antagonist, not monotherapy. ### Mechanism of Androgen Suppression ```mermaid flowchart TD A[Hypothalamus]:::action --> B[GnRH]:::action B --> C[Anterior Pituitary]:::action C --> D[LH/FSH]:::action D --> E[Leydig Cells]:::action E --> F[Testosterone]:::outcome F --> G[Androgen Receptor]:::outcome G --> H[Prostate Cancer Growth]:::urgent I[GnRH Agonist/Antagonist]:::action -.blocks.-> B J[AR Antagonist]:::action -.blocks.-> G ``` ### Comparison of First-Line Hormonal Strategies | Agent/Strategy | Mechanism | Efficacy | Use Case | Limitation | |---|---|---|---|---| | **GnRH agonist (Leuprolide) alone** | ↓ LH → ↓ Testosterone | Partial castration | Monotherapy in low-burden disease | Testosterone flare; incomplete suppression of adrenal androgens | | **GnRH agonist + AR antagonist (CAB)** | ↓ LH + blocks AR | Superior survival in mCSPC | **First-line for mCSPC** | More side effects; cost | | **AR antagonist (Bicalutamide) monotherapy** | Blocks AR only | Incomplete; testosterone rises | Monotherapy only in non-metastatic CRPC | Inferior in metastatic disease; testosterone escape | | **Abiraterone (CYP17 inhibitor)** | ↓ Adrenal androgens | Excellent in CRPC | **Second-line** (after GnRH + AR antagonist) | Not first-line; requires glucocorticoid; hepatotoxicity | | **Enzalutamide (2nd-gen AR antagonist)** | Blocks AR (potent) | Excellent in CRPC | **Second-line** (after GnRH + AR antagonist) | Not first-line monotherapy | ### Why Complete Androgen Blockade? **High-Yield:** CAB (GnRH agonist + AR antagonist) provides: 1. **Suppression of testicular androgens** (via GnRH agonist → castration) 2. **Blockade of adrenal androgens** (via AR antagonist) 3. **Survival benefit** in mCSPC (meta-analyses show ~5–10% improvement in OS) 4. **Delays time to progression** and CRPC conversion **Clinical Pearl:** The initial testosterone flare from GnRH agonist monotherapy can worsen bone pain and urinary obstruction; adding an AR antagonist 1–2 weeks before GnRH agonist prevents this. ## Why Other Options Are Incorrect - **Bicalutamide monotherapy:** Inferior in metastatic disease; causes testosterone rise via feedback; monotherapy is acceptable only in non-metastatic CRPC - **Abiraterone:** Second-line agent, used after progression on GnRH + AR antagonist; not first-line - **Enzalutamide:** Second-line agent; superior to abiraterone in some trials but not first-line monotherapy